Is sirolimus albumin-bound nanoparticle injection (FYARRO) included in medical insurance?

Sirolimus albumin-bound nanoparticle injection (FYARRO) is a prescription medicine used to treat adults with malignant perivascular epithelioid cell tumors (PEComa) that have spread to other parts of the body (metastatic) or cannot be removed with surgery (locally advanced, unresectable). It is unclear whether sirolimus albumin-bound nanoparticle injection is safe and effective in patients with severe liver disease or children. Do not use sirolimus albumin-bound nanoparticle injection if the patient has a severe allergic reaction to sirolimus or other sirolimus-like drugs (such as everolimus, temsirolimus) or human albumin. Following administration of the recommended dose of sirolimus albumin-bound nanoparticle injection, the estimated mean (%CV) Cmax and AUC 0-inf of sirolimus in patients with advanced solid tumors were 2590 ng/mL (30% CV) and 22100 ng*h/mL (50% CV), respectively.

The original drug of sirolimus albumin-bound nanoparticle injection is a new type of drug for treating diseases. It is not currently on the market in China and therefore is not included in medical insurance. The common dosage form of sirolimus albumin-bound nanoparticle injection original drug is injection, which has been marketed overseas. US version specifications The price of each 100mg tube may be around RMB 60,000 (the price may fluctuate due to the exchange rate), which is relatively expensive. Currently, there is no generic version of Sirolimus Albumin-Bound Nanoparticle Injection on the market. For more drug information and specific prices, please consult Yaode Medical Consultants.